Mergers and acquisition in the pharmaceutical and life-sciences sector have been a mixed bag in the first half of 2021. The total value and number of deals increased exponentially compared…
The COVID-19 pandemic gave rise to innovation in conducting clinical trials, including decentralized and direct-to-patient services. Will this trend continue, and what may be the impact on clinical trial material…
Mid-Year CDMO Review: COVID-19 Vaccine Manufacturing and M&A
What have been the key developments in 2021 thus far in the CDMO market? Increasing participation by CDMOs in COVID-19 vaccine manufacturing and robust mergers and acquisition activity have marked…
Market Watch: Cell and Gene Therapies, Niche But Growing
Cell and gene therapies are a niche, but growing part of the bio/pharma industry. DCAT Value Chain Insights looks at key market activity: number of developers, commercial products, pipelines, and…
How are small molecules & biologics trending among new drug approvals and potential blockbuster drugs? Will biologics overtake small molecules as the leading modality, and if so, in what areas?…
Despite significant disruption and reprioritization of clinical trial activity during 2020 due to COVID-19, R&D activity levels remained at historically high levels, driven by new funding and strategic transactions, especially…
The European Commission has updated the EU’s Industrial Strategy, which was first put forth in March 2020 with goals of realizing a green and digital economy while increasing the EU’s…
Continuous Manufacturing and Pharma: Where Does it Stand?
The bio/pharma industry is based on batch manufacturing, so how is the adoption of continuous manufacturing for drug substances and drug products progressing? A pending ICH guideline clarifies technical and…
COVID-19 and the Bio/Pharma Industry: The Bottom Line
What has been the impact of COVID-19 on bio/pharmaceutical companies’ bottom line? For companies successfully bringing products for COVID-19 to fruition, 1Q 2021 results have been positive. What is expected…
Into the Future: 3D Printing and Solid Dosage Drugs
Three-dimensional (3D) printing is an emerging technology across multiple industries, including the bio/pharmaceutical industry. To date, one drug using 3D printing has been approved by the FDA. What’s behind the…
